The glucagon-like peptide-1 receptor agonists (GLP-1 RAs) (lixisenatide, liraglutide, semaglutide, exenatide, albiglutide, and dulaglutide) represent one of the two categories of drugs indicated for the T2DM treatment that act on the incretin system [169]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.